Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jul 01, 2011 (Vol. 31, No. 13)


  • Various resource types
  • Lacking in content in places

Don’t worry, this isn’t a website for one of those pesky commercials you see on TV. (Send us your gold jewelry in an unmarked envelope…) Rather, this is the Genomics Of Lipid-associated Disorders DataBase. (I know, I know, that was your next guess, wasn’t it?) The goal of the site is to “integrate disparate information on the function and properties” of genes and proteins involved in disorders such as atherosclerosis and various hyperlipidemias. To that end, the site does a nice job of bringing together different types of information, as is reflected in the major categories into which the site is divided: pathways, datasets, tools, protocols, reagents, and links. Content is definitely sparse in areas, but the website fills a unique medical niche such that I hope the people behind it continue to expand its resources.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »